GS-9911 / Gilead, Carna Biosci - LARVOL DELTA

Study of GS-9911 With or Without Antibody Treatment for Adults With Solid Tumors (clinicaltrials.gov) - P1 | N=45 | Active, not recruiting | Sponsor: Gilead Sciences | Recruiting ➔ Active, not recruiting | N=120 ➔ 45

Enrollment change • Enrollment closed • Monotherapy • Solid Tumor

Gilead culls…2 cancer assets (FierceBiotech) - "After the recent approval and launch of twice-yearly HIV prophylactic Yeztugo, Gilead is cleaning up its R&D pipeline. The Bay Area company has dropped two early-stage cancer candidates....The two culled oncology assets are a DGKα inhibitor called GS-9911 and an MCL1 inhibitor called zamzetoclax or GS-9716, according to an Aug. 7 earnings presentation. Both were being tested out in phase 1 trials, with GS-9911 being tested alone and in combination with an anti-PD-1 monoclonal antibody in patients with advanced solid tumors, and zamzetoclax alone or with other chemotherapies in patients with advanced solid malignancies. Gilead did not respond to Fierce Biotech's questions about the current status of the trials."

Pipeline update • Solid Tumor

Study of GS-9911 With or Without Antibody Treatment for Adults With Solid Tumors (clinicaltrials.gov) - P1 | N=120 | Recruiting | Sponsor: Gilead Sciences

Combination therapy • Metastases • Monotherapy • Trial completion date • Trial primary completion date • Oncology • Solid Tumor

Study of GS-9911 With or Without Antibody Treatment for Adults With Solid Tumors (clinicaltrials.gov) - P1 | N=120 | Recruiting | Sponsor: Gilead Sciences | Not yet recruiting ➔ Recruiting

Combination therapy • Enrollment open • Metastases • Monotherapy • Oncology • Solid Tumor

Study of GS-9911 With or Without Antibody Treatment for Adults With Solid Tumors (clinicaltrials.gov) - P1 | N=120 | Not yet recruiting | Sponsor: Gilead Sciences

Combination therapy • Metastases • Monotherapy • New P1 trial • Oncology • Solid Tumor